ArticleScientific reports2025
Comprehensive multiomics profiling reveals the protective function of gypenosides against dextran sulfate sodium-induced colitis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gypenosides Mitigate STEC-Induced Intestinal Injury Through Modulation of Ferroptosis Involving the ATF4-CHAC1-GPX4 Axis.Antioxidants (Basel, Switzerland) · 2026Article
- Carrier-free supramolecular architectonics of quercetinMaterials today. Bio · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
In this study, we determined whether gypenosides exert a therapeutic effect on colitis. We then explored the underlying mechanism of gypenosides in the treatment of ulcerative colitis (UC) via multiomics analyses. Dextran sulfate sodium (DSS) was used to establish a UC model in mice, and a subgroup of colitis model mice was subjected to gypenosides intervention. The inflammatory manifestations of the model and drug groups were determined via histological and molecular experiments. In addition, tissue and blood samples were collected for transcriptome and metabolomics analysis, respectively. Immunohistochemistry was used to detect the key proteins involved in UC pathogenesis and drug intervention. By combining transcriptomics and metabolomics assays, we explored one of the possible mechanisms by which gypenosides ameliorate UC in mice. Gypenosides treatment significantly alleviated clinical symptoms, prevented colon shortening, and decreased the disease activity index (DAI) in an 3% DSS-induced UC mouse model. Transcriptome sequencing revealed that the intestinal stem genes Ascl2 and Lgr5 ranked forefront in terms of differential expression before and after intervention with gypenosides. The metabolomics results suggest that the tricarboxylic acid cycle (TCA) and amino acid metabolism (AM) were the main metabolic pathways associated with UC and gypenosides treatment. Taken together, these results suggest that gypenosides may affect the biological activity of stem cells by regulating the tricarboxylic acid cycle and glutamine metabolism, promoting the repair of the damaged mucosa. In this study, we demonstrated that gypenosides alleviate colitis, likely by regulating the expression of genes associated with stemness and modulating the tricarboxylic acid cycle and amino acid metabolism, in a DSS-induced colitis mouse model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.